Gilead Partnered with Clinton Health Access Initiative and the Pentato to Advance the Development of Dispersible Pediatric Therapies for Children with HIV
- Gilead partnered with CHAI and the Penta to advance the development, regulatory approval, and commercialization of dispersible pediatric HIV medicines who live in LMICs
- For a dispersible version of F/TAF (a pediatric formulation containing emtricitabine and tenofovir alafenamide), Gilead will transfer the technology together with supporting PK data
- Gilead is also partnering with Monell Chemical Senses Center (Monell), Eurofins’ Translational Cell Models group (formerly known as DiscoveryBiomed, Inc.), and CHAI to determine bitter blockers for pediatric formulations of the medications TAF and SOF (pediatric formulations of sofosbuvir)
Ref: Businesswire | Image: Gilead
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at email@example.com
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.